Oral Cancer: From Pathophysiology to Novel Therapeutic Approach
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 93
Special Issue Editor
Interests: natural products; oxidative stress; patient-derived xenograft animal models; cancer therapy and diagnosis; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Oral cancer continues to be a significant global health concern, with rising incidence rates and persistent challenges in early detection, treatment resistance, and disease recurrence. This Special Issue comprehensively explores the molecular mechanisms, cellular interactions, and genetic predispositions underlying oral cancer pathophysiology. Additionally, it highlights emerging diagnostic strategies and novel therapeutic approaches that have the potential to improve patient outcomes. Key topics covered in this issue include molecular and cellular mechanisms, biomarkers for early detection and prognosis, targeted and immunotherapeutic strategies, and precision medicine and personalized therapies. By compiling innovative research and expert reviews, this Special Issue bridges the gap between fundamental research and clinical application, promoting the development of more effective strategies for the prevention, diagnosis, and treatment of oral cancer. Researchers, clinicians, and healthcare professionals are encouraged to contribute their findings and foster interdisciplinary collaborations to combat this devastating disease.
Dr. Chan-Yen Kuo
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oral cancer and pathophysiology
- molecular mechanisms
- biomarkers
- immunological and targeted therapy
- precision medicine and personalized therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
